/Bio-Techne%20Corp%20logo%20and%20data-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
Based in Minneapolis, Minnesota, Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets. Valued at a market cap of $11.6 billion, the company boasts an extensive catalog of over 500,000 biotechnology products and scientific tools. The company is expected to announce its fiscal Q1 earnings results before the market opens on Wednesday, Oct. 30.
Ahead of this event, analysts project the biotech company to report a profit of $0.34 per share, down 2.9% from $0.35 per share in the year-ago quarter. The company has surpassed Wall Street's bottom-line estimates in two of the last four quarters while missing on other two occasions. In Q4 2024, the company reported an EPS of $0.49, which topped the consensus estimates by 11.4%. The results were primarily driven by a 15% year-over-year growth in revenues from its diagnostics and genomics segment, leading to a 2% annual growth in revenues in the quarter.
